Estimation of indocyanine green elimination rate constant k and retention rate at 15 min using patient age, weight, bilirubin, and albumin

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 16, Issue 4, 2009, Pages 521-528

  Kim, Ga Yeong ^a   Bae, Kyun Seop ^b   Noh, Gyu Jeong ^b   Min, Won Ki ^b  

^a Korea University Ansan Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

ICG clearance; ICG k; ICG R15; NONMEM; Population pharmacokinetics; Sampling time point

Indexed keywords

ALBUMIN; BILIRUBIN; INDOCYANINE GREEN;

ACCURACY; ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ANALYZER; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG RETENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE MEASUREMENT SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; BODY WEIGHT; FEMALE; HUMANS; INDOCYANINE GREEN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; YOUNG ADULT;

EID: 67650548131     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-009-0097-3     Document Type: Article

References (33)

1. Jacob M, Conzen P, Finsterer U, et al. Technical and physiological background of plasma volume measurement with indocyanine green: A clarification of misunderstandings. J Appl Physiol. 2007;102:1235-42.
2. Hemming AW, Scudamore CH, Shackleton CR, et al. Indocyanine green Cl as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg. 1992;163:515-8.
3. Hori T, Iida T, Yagi S, et al. K(ICG) value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. Liver Transpl. 2006;12:605-13.
4. Sakka SG. Assessing liver function. Curr Opin Crit Care. 2007;13:207-14.
5. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am. 2004;84:355-73.
6. Sekimoto M, Fukui M, Fujita K. Plasma volume estimation using indocyanine green with biexponential regression analysis of the decay curves. Anaesthesia. 1997;52:1166-72.
7. Cherrick GR, Stein SW, Leevy CM, et al. Indocyanine green: Observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960;39:592-600.
8. Wheeler HO, Cranston WI, Meltzer JI. Hepatic uptake and biliary excretion of indocyanine green in the dog. Proc Soc Exp Biol Med. 1958;99:11-4.
9. Nambu M, Namihisa T. Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect. J Gastroenterol. 1996;31:228-36.
10. Ott P. Hepatic elimination of indocyanine green with special reference to distribution kinetics and the influence of plasma protein binding. Pharmacol Toxicol. 1998;83 Suppl 2:1-48.
11. Ott P, Bass L, Keiding S. Hepatic ICG removal in the pig depends on plasma protein and hematocrit: Evidence of sinusoidal binding disequilibrium and unstirred water layer effects. Hepatology. 1997;26:679-90.
12. Tsubono T, Todo S, Jabbour N, et al. Indocyanine green elimination test in orthotopic liver recipients. Hepatology. 1996;24:1165-71.
13. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-52.
14. Gao L, Ramzan I, Baker AB. Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery. Anaesth Intensive Care. 2000;28:375-85.
15. Maruyama S, Hirayama C, Yamamoto S, et al. Hyperendothelinemia and ICG Cl in alcoholic and nonalcoholic cirrhosis. Dig Dis Sci. 2002;47:773-7.
16. Kinoshita K, Maruo S. Population pharmacokinetic analysis of indocyanine green retention rate at 15 minutes. Rinsho Byori. 1990;38:906-10.
17. Lee SG, Hwang S. How I do it: Assessment of hepatic functional reserve for indication of hepatic resection. J Hepatobiliary Pancreat Surg. 2005;12:38-43.
18. Beal S, Sheiner L. NONMEM User's guides Part V. Introductory guide. San Francisco: NONMEM Project Group, University of California; 1992.
19. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
20. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119-33.
21. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59:19-29.
22. Shinohara H, Tanaka A, Kitai T, et al. Direct measurement of hepatic indocyanine green Cl with near-infrared spectroscopy: Separate evaluation of uptake and removal. Hepatology. 1996;23:137-44.
23. Grygiel JJ, Ward H, Ogborne M, et al. Relationships between plasma theophylline Cl, liver volume and body weight in children and adults. Eur J Clin Pharmacol. 1983;24:529-32.
24. Evans WE, Relling MV, de Graaf S, et al. Hepatic drug Cl in children: studies with indocyanine green as a model substrate. J Pharm Sci. 1989;78:452-6.
25. Erdogan D, Heijnen BH, Bennink RJ, et al. Preoperative assessment of liver function: A comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green Cl test. Liver Int. 2004;24:117-23.
26. Mizuguchi T, Katsuramaki T, Nobuoka T, et al. Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy. World J Surg. 2004;28:971-6.
27. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231-9.
28. Fujioka H, Kawashita Y, Kamohara Y, et al. Utility of technetium-99m-labeled-galactosyl human serum albumin scintigraphy for estimating the hepatic functional reserve. J Clin Gastroenterol. 1999;28:329-33.
29. Merkel C, Gatta A, Zoli M, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG Cl in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci. 1991;36:1197-203.
30. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805.
31. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-70.
32. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-71.
33. Furrer K, Deoliveira ML, Graf R, et al. Improving outcome in patients undergoing liver surgery. Liver Int. 2007;27:26-39.